Oncology Epidemiology, Risk Factors
Conditions
Keywords
H. Pylori, Guadeloupe, stomach cancer
Brief summary
The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations. The main objective of the study is to estimate the prevalence of H. Pylori detected by immunohistochemistry in patients newly diagnosed with cancer.
Detailed description
Stomach cancer is the 4th most common cancer site in the world and the 3rd cause of mortality. It is associated with infection by the Helicobacter Pylori bacterium, which colonizes the gastric mucosa in 80% of cases. The decrease of the prevalence of H. pylori infection in developed countries with the advent of antibiotic treatments is responsible for the decrease in the incidence of stomach cancer. But in the French West Indies, stomach cancer remains in excess incidence and mortality compared to France. The prevalence of H. pylori infection remains unknown, both in general population and in patients with stomach cancer. Eating habits combining high consumption of salt, meat and smoked fish could partly explain these high incidences. Furthermore, recent observations suggest that environmental risk factors (pesticides pollution) could also be involved in the occurrence of this cancer. Estimating the prevalence of H. pylori in stomach cancers will improve the epidemiological knowledge of this cancer with high incidence rates and prevention measures.
Interventions
None listed
Sponsors
Centre Hospitalier Universitaire de la Guadeloupe
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer * Patient having read the information note and having signed the consent to participate in the study * Patient with social security coverage.
Exclusion criteria
* Refusal to participate. * Patient who could not answer the questionnaires * Patient not affiliated to a social security scheme * Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.) * Pregnant or breastfeeding woman * Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| detection of H. Pylori in immunohistochemistry | Baseline | Detection of Helicobacter pylori will be performed by immunohistochemistry (IHC) on gastric biopsy samples collected at inclusion. The procedure aims to identify the presence of H. pylori antigens within the gastric mucosa using specific antibodies. The test will be conducted in a certified pathology laboratory according to standard diagnostic protocols. Results will be reported as positive or negative for H. pylori infection. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| positivity of anti H. Hylori serology by Elisa test | Baseline | Positivity of anti-Helicobacter pylori serology determined by ELISA test performed on serum samples collected at inclusion. Results will be reported as positive or negative for H. pylori antibodies. |
Countries
Guadeloupe
Contacts
Primary ContactMélanie petapermal, Master degree
Backup ContactValérie Hamony Soter
Outcome results
None listed